Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...
July 2022
Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases
"29/06/2022
Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO). The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates. "